Group One Trading, L.P. Arrowhead Pharmaceuticals, Inc. Transaction History

Group One Trading, L.P.

$3.01 Billion
Q2 2024

A detailed history of Group One Trading, L.P. transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Group One Trading, L.P. holds 586 shares of ARWR stock, worth $12,177. This represents 0.0% of its overall portfolio holdings.

Number of Shares

586

Holding current value

$12,177

% of portfolio

0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$21.87 - $28.24 $12,815 - $16,548	586 New	586 $15,000
Q4 2023 Feb 14, 2024	BUY	$21.2 - $31.03 $41,318 - $60,477	1,949 Added 48.59%	5,960 $182,000
Q3 2023 Nov 09, 2023	SELL	$26.2 - $36.08 $253,878 - $349,615	-9,690 Reduced 70.72%	4,011 $107,000
Q2 2023 Aug 09, 2023	BUY	$25.16 - $41.38 $152,041 - $250,059	6,043 Added 78.91%	13,701 $488,000
Q1 2023 May 12, 2023	SELL	$23.68 - $38.51 $712,768 - $1.16 Million	-30,100 Reduced 79.72%	7,658 $194,000
Q4 2022 Feb 09, 2023	BUY	$28.0 - $40.56 $432,572 - $626,611	15,449 Added 69.25%	37,758 $1.53 Million
Q3 2022 Nov 09, 2022	BUY	$29.63 - $48.31 $143,231 - $233,530	4,834 Added 27.66%	22,309 $737,000
Q2 2022 Aug 11, 2022	SELL	$27.79 - $50.61 $51,744 - $94,235	-1,862 Reduced 9.63%	17,475 $615,000
Q1 2022 May 12, 2022	SELL	$39.62 - $69.97 $2.28 Million - $4.02 Million	-57,443 Reduced 74.82%	19,337 $889,000
Q4 2021 Feb 11, 2022	BUY	$58.09 - $82.51 $23,236 - $33,004	400 Added 0.52%	76,780 $5.09 Million
Q3 2021 Nov 12, 2021	BUY	$58.38 - $84.96 $662,904 - $964,720	11,355 Added 17.46%	76,380 $4.77 Million
Q2 2021 Aug 10, 2021	SELL	$62.15 - $90.32 $145,493 - $211,439	-2,341 Reduced 3.48%	65,025 $5.39 Million
Q1 2021 May 12, 2021	BUY	$61.35 - $90.47 $1.87 Million - $2.75 Million	30,416 Added 82.32%	67,366 $4.47 Million
Q4 2020 Feb 10, 2021	SELL	$43.82 - $85.37 $1.63 Million - $3.17 Million	-37,154 Reduced 50.14%	36,950 $2.84 Million
Q3 2020 Nov 12, 2020	BUY	$33.21 - $51.27 $1.66 Million - $2.57 Million	50,033 Added 207.86%	74,104 $3.19 Million
Q2 2020 Aug 13, 2020	SELL	$26.12 - $43.27 $1.63 Million - $2.69 Million	-62,278 Reduced 72.12%	24,071 $1.04 Million
Q1 2020 May 13, 2020	BUY	$20.56 - $63.12 $1.29 Million - $3.95 Million	62,627 Added 264.0%	86,349 $2.48 Million
Q4 2019 Feb 10, 2020	BUY	$28.14 - $73.01 $132,454 - $343,658	4,707 Added 24.75%	23,722 $1.51 Million
Q3 2019 Nov 12, 2019	BUY	$26.26 - $34.86 $499,333 - $662,862	19,015 New	19,015 $536,000
Q2 2019 Aug 09, 2019	SELL	$17.43 - $28.82 $435,872 - $720,701	-25,007 Closed	0 $0
Q1 2019 May 13, 2019	SELL	$12.05 - $20.18 $155,553 - $260,503	-12,909 Reduced 34.05%	25,007 $459,000
Q4 2018 Feb 06, 2019	BUY	$10.74 - $19.7 $407,217 - $746,945	37,916 New	37,916 $471,000
Q3 2018 Nov 08, 2018	SELL	$14.0 - $20.3 $109,102 - $158,197	-7,793 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$6.37 - $14.02 $388,219 - $854,448	-60,945 Reduced 88.66%	7,793 $106,000
Q1 2018 May 11, 2018	BUY	$3.72 - $7.64 $255,705 - $525,158	68,738 New	68,738 $496,000
Q3 2017 Nov 15, 2017	SELL	$1.69 - $4.33 $178,443 - $457,196	-105,588 Closed	0 $0
Q2 2017 Aug 14, 2017	BUY	N/A	105,588	105,588 $171,000

Others Institutions Holding ARWR

# of Institutions

295

Shares Held

92.3M

Call Options Held

1.33M

Put Options Held

549K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.2B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.

Account

Group One Trading, L.P. Arrowhead Pharmaceuticals, Inc. Transaction History